Dexanabinol
March 19, 2004 by admin · Leave a Comment
On March 15, 2004 Pharmos Corporation announced that it had completed patient enrollment in its pivotal Phase III study of dexanabinol for the treatment of severe traumatic brain injury (TBI). A total of 86 trauma centers recruited 860 patients. Pharmos expects to unblind the study data and announce initial results toward the end of this [...]